pharmacological considerations in optimal integrase inhibitors clinical care | marta boffito
Published 3 years ago • 210 plays • Length 53:08
Download video MP4
Download video MP3
Similar videos
-
23:08
pharmacological considerations when choosing optimal treatment regimen - marta boffito
-
18:53
pharmacological considerations in the complex hiv patient | marta boffito md, phd, frcp
-
27:43
pharmacological characteristics and delivery options of the integrase inhibitors | david back, phd
-
31:02
pharmacological characteristics and delivery options of the integrase inhibitors | courtney fletcher
-
25:31
integrating science into the clinic: current and future use of ... | marta boffito, md, phd, frcp
-
1:30:03
session 2: reduced drug regimens: scientific considerations | full livestream
-
21:40
clinical pharmacology of long-acting therapy - marta boffito, md, phd, frcp
-
26:27
pharmacological considerations in choice of regimen - saye khoo, md, phd
-
6:24
an update on my lung function
-
17:31
mini-lecture series: bictegravir-tenofovir alafenamide-emtricitabine
-
7:55
mini-lecture series: dolutegravir-rilpivirine
-
20:55
optimizing clinical utility of integrase inhibitors | anton pozniak, md, frcp
-
18:36
use of insti in patients with comorbidities and polypharmacy - marta boffito, md, phd, frcp
-
26:15
basic science of integrase inhibitors | charles boucher, md, phd
-
29:19
clinical pharmacology related considerations | david back, phd
-
10:02
pharmacokinetics of la cab - marta boffito, md, phd, frcp
-
19:28
novel drug delivery systems | marta boffito, md, phd, frcp
-
11:55
basic science of integrase inhibitors | mark wainberg, md
-
26:14
important drug-drug interactions in women aging with hiv | marta boffito, md, phd
-
0:47
liverpool course 2021 - marta boffito - improving patient outcomes through better management of ddis
-
26:01
clinical case presentation | marta boffito, md, phd, frcp
-
12:55
clinical case presentation: switching therapy before/during pregnancy - marta boffito, md, frcp
Clip.africa.com - Privacy-policy